Mucocutaneous manifestations affect over 80% of patients with systemic lupus erythematosus (SLE) and can significantly impact on patient quality of life. touchIMMUNOLOGY were delighted to speak with Prof. Jorge Sanchez-Guerrero (University of Toronto, Toronto, ON, Canada) around his post hoc analysis investigating the effects of belimumab on the mucocutaneous manifestations of SLE.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘Belimumab Effects on Skin in Patients with Systemic Lupus Erythematosus: A Pooled Post Hoc Analysis of Five Phase 3, Randomized, Placebo-Controlled Clinical Trials.‘ (Abstract number: 0979) was presented at the ACR Convergence, November 10–14, 2022.
Questions
- Could you tell us a little about mucocutaneous manifestations of systemic lupus erythematosus (SLE) and their impact on quality of life? (0:16)
- What is known about the efficacy and safety of belimumab therapy in SLE? (1:34)
- What were the aims, methodology and eligibility criteria of this post-hoc analysis? (3:07)
- What were the study findings? (4:00)
- What do you consider the role of belimumab in the treatment paradigm for SLE? (5:28)
Disclosures: Jorge Sanchez-Guerrero discloses consulting for Biogen; and serving on advisory boards for EMD Serono.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.
Filmed in coverage of the ACR Convergence 2022.
